Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer

被引:75
作者
Petrillo, Marco [1 ]
Zannoni, Gian Franco [2 ]
Tortorella, Lucia [1 ]
Anchora, Luigi Pedone [1 ]
Salutari, Vanda [1 ]
Ercoli, Alfredo [3 ]
Margariti, Pasquale Alessandro [1 ]
Scambia, Giovanni [1 ]
Fagotti, Anna [4 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Obstet & Gynecol, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Human Pathol, I-00168 Rome, Italy
[3] Policlin Abano Terme, Dept Obstet & Gynecol, Padua, Italy
[4] Univ Perugia, St Maria Hosp, Dept Surg, Div Minimally Invas Gynecol Surg, Terni, Italy
关键词
advanced ovarian cancer; complete pathological response; interval debulking surgery; neoadjuvant chemotherapy; prognosis; PRIMARY SURGICAL DEBULKING; ADVANCED-STAGE OVARIAN; SURGERY; SURVIVAL; CARCINOMA; METAANALYSIS; MUTATIONS; CRITERIA;
D O I
10.1016/j.ajog.2014.06.034
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The objective of the study was to analyze in a large series of unresectable advanced ovarian cancer (AOC) patients the prognostic role of pathological response to neoadjuvant chemotherapy (NACT). STUDY DESIGN: We retrospectively evaluated 322 unresectable AOC patients treated with NACT followed by interval debulking surgery (IDS). Pathological response was classified as follows: complete (cPR) in the absence of residual disease, microscopic (microPR) in the presence of microscopic tumor foci (maximum diameter <= 3 mm), and macroscopic (macroPR) when macroscopic residual disease was detected. RESULTS: cPR was observed in 21 (6.5%), microPR in 104 (32.3%), and macroPR in 197 (61.2%) patients. No differences were observed in the distribution of baseline clinicopathological characteristics between the groups. Median progression-free survival was 36 months in cPR, 16 in microPR, and 13 in macroPR (P = .001). Median overall survival was 72 months in cPR, 38 in microPR, and 29 in macroPR P = .018). The survival differences between microPR and macroPR patients were not confirmed when the analysis included only cases resected to no gross residual disease at IDS. cPR retained the independent prognostic role in the multivariate analysis. International Federation of Gynecology and Obstetrics stage IV was the only negative independent predictor of cPR (chi(2) = 5.362, P = .021). CONCLUSION: cPR is an uncommon event in AOC patients receiving NACT and is associated with a longer progression-free survival and overall survival compared with women showing no cPR, even in patients receiving IDS with no gross residual disease. The proposed classification of pathological response may serve in the next future as an easily assessable and highly valuable prognostic tool in this clinical setting.
引用
收藏
页码:632.e1 / 632.e8
页数:8
相关论文
共 23 条
[1]   Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer [J].
Aletti, GD ;
Dowdy, SC ;
Podratz, KC ;
Cliby, WA .
GYNECOLOGIC ONCOLOGY, 2006, 100 (02) :283-287
[2]  
[Anonymous], COCHRANE DATABASE SY
[3]  
[Anonymous], N ENGL J MED
[4]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[5]   An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) [J].
Chi, Dennis S. ;
Musa, Fernanda ;
Dao, Fanny ;
Zivanovic, Oliver ;
Sonoda, Yukio ;
Leitao, Mario M. ;
Levine, Douglas A. ;
Gardner, Ginger J. ;
Abu-Rustum, Nadeem R. ;
Barakat, Richard R. .
GYNECOLOGIC ONCOLOGY, 2012, 124 (01) :10-14
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer [J].
Dann, Rebecca Byler ;
DeLoia, Julie A. ;
Timms, Kirsten M. ;
Zorn, Kristin K. ;
Potter, Jennifer ;
Flake, Darl D., II ;
Lanchbury, Jerry S. ;
Krivak, Thomas C. .
GYNECOLOGIC ONCOLOGY, 2012, 125 (03) :677-682
[8]   Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) [J].
du Bois, Andreas ;
Reuss, Alexander ;
Pujade-Lauraine, Eric ;
Harter, Philipp ;
Ray-Coquard, Isabelle ;
Pfisterer, Jacobus .
CANCER, 2009, 115 (06) :1234-1244
[9]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[10]   Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study [J].
Eisenkop, SM ;
Spirtos, NM ;
Friedman, RL ;
Lin, WCM ;
Pisani, AL ;
Perticucci, S .
GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :390-396